Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precemtabart Tocentecan +/- Bevacizumab vs FTD-TPI + Bevacizumab in Previously Treated Metastatic Colorectal Cancer
NCT07549412Phase 3Recruiting
- Sponsor
- EMD Serono
- Start
- May 2026
- Primary completion
- Oct 2029
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of precemtabart tocentecan in metastatic colorectal cancer (mCRC) (3 arms), sponsored by EMD Serono. Primary endpoint: Overall Survival at 19 months. Started May 2026; status: recruiting.
02
Drugs
precemtabart tocentecan
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT07549412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07549412.